Traws Pharma, Inc., formerly Onconova Therapeutics, Inc., is a virology and oncology company. Co. is engaged in developing antivirals for influenza, COVID and other respiratory infections and narazaciclib. Its proprietary portfolio includes, TRX100 (viroksavir), TRX01 (travaltrevir), and Narazaciclib. Viroksavir is a cap-dependent endonuclease inhibitor for influenza. Travaltrevir is a Mpro protease inhibitor for COVID19. Narazaciclib is a cyclin-dependent kinases (CDK) 4/6 inhibitor for low-grade endometrioid endometrial cancer (LGEEC). We show 8 historical shares outstanding datapoints in our coverage of TRAW's shares outstanding history.
Understanding the changing numbers of TRAW shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like TRAW versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching TRAW by allowing them to research TRAW shares outstanding history
as well as any other stock in our coverage universe. |
Free TRAW Email Alerts:
Video: Shares Outstanding Importance
